Navigation Links
United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
Date:10/10/2011

SILVER SPRING, Md., Oct. 10, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.  Based on the support from this contract, approximately 20 jobs will be created at Unither Virology's headquarters in Silver Spring, Maryland, with additional jobs created at subcontractor organizations.

"I'm pleased with the development of our broad-spectrum antiviral program, which is in the preclinical stage," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "The overall objective for this partnership with NIH is to develop a safe and orally available broad-spectrum antiviral drug to treat viruses such as dengue and influenza.  Dengue is a painful mosquito-borne tropical fever suffered by millions of patients worldwide each year, and this program may help provide a path to treatment.  It is also rewarding to see how our industry generates dozens of jobs when the science data justify expanding a program to its next stage of growth."

The contract provides for up to approximately $45 million in total funding over five years.  The base period of 42 months includes approximately $10.6 million in funding.  The remaining funds are allocated to eight milestone-based options.  Funding will support the development of a candidate compound through preclinical safety and efficacy studies toward potential clinical trials against dengue, as well as preclinical studies to develop additional data against influenza.

About United Therapeutics Corporation

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

About Unither Virology

Unither Virology, LLC is a wholly-owned subsidiary of United Therapeutics Corporation. The company is the preclinical stage of developing a broad-spectrum antiviral drug to treat multiple viruses, such as dengue and influenza. Drug candidates have been shown to protect animals against multiple viruses, and the company is commencing a program to move toward potential clinical trials.

The company's glycobiology antiviral agents are being developed under a research agreement with the Oxford Glycobiology Institute. The antiviral agents consist of iminosugar molecules, which enter host cells and inhibit the chemical pathways that viruses use to fold their proteins. Because the iminosugars affect the host cell, rather than attacking the virus directly, they reduce the chance for drug-resistant virus strains to emerge. In laboratory tests, the iminosugar molecules have shown activity against several families of viruses. Unither Virology is conducting ongoing in vivo tests.

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our expectations regarding the receipt of up to approximately $45 million in funding from NIH, the timing of any such funding, the prospects for future job creation and our ability to develop a broad-spectrum antiviral drug. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.  These risks and uncertainties include, among others, the possible decision by NIH not to exercise some or all of its options under our contract, and potential negative results under preclinical or clinical studies. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of October 10, 2011, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Full-day "United Nations" Online Investor Conference: October 6th at RetailInvestorConferences.com
2. United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
3. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
4. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
5. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
6. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
7. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
8. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
9. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
10. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
11. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... 2016 , ... STACS DNA Inc., the sample tracking software company, today announced ... has joined STACS DNA as a Field Application Specialist. , “I am thrilled ... COO of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/9/2016)... Paris Police Prefecture ... solution to ensure the safety of people and operations in ... major tournament Teleste, an international technology group specialised ... today that its video security solution will be utilised by ... public safety across the country. The system roll-out is scheduled ...
Breaking Biology News(10 mins):